↓ Skip to main content

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Overview of attention for article published in New England Journal of Medicine, June 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Readers on

mendeley
1040 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 554 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 1,040 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 1040 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 108 10%
Student > Bachelor 96 9%
Student > Ph. D. Student 91 9%
Student > Master 58 6%
Other 49 5%
Other 159 15%
Unknown 479 46%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 192 18%
Biochemistry, Genetics and Molecular Biology 89 9%
Immunology and Microbiology 57 5%
Agricultural and Biological Sciences 33 3%
Pharmacology, Toxicology and Pharmaceutical Science 29 3%
Other 140 13%
Unknown 500 48%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1422. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 October 2026.
All research outputs
#10,620
of 34,752,441 outputs
Outputs from New England Journal of Medicine
#503
of 38,721 outputs
Outputs of similar age
#143
of 400,336 outputs
Outputs of similar age from New England Journal of Medicine
#4
of 269 outputs
Altmetric has tracked 34,752,441 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 38,721 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 120.0. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 400,336 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 269 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.